Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Clinical manifestations of Alzheimer�s disease (AD) are complex and heterogeneous, far from restricted to the progressive
loss of learning and memory. Loss of judgment and executive functions together with the early appearance of Behavioral
and Psychological Symptoms of Dementia [BPSD] are considered a strong source of distress and burden for the patients and
caregivers. Actually, growing number of studies assessing AD therapeutic strategies targeting mnemonic effects also look for
benefits on these other symptoms. At the preclinical level, behavioral neuroscience has confronted the difficulty of modeling
this clinical heterogeneity in experimental animals and scarce literature examine the whole array of symptoms. The author
will summarize the findings obtained in the Spanish colony of 3xTg-AD mice using a multidimensional behavioral screening
approach (functional, BPSD and cognition, social) together with other levels of study (cellular, neurochemical, physiological,
immunoendocrine and neuropathological). Evidence of appearance of BPSD-like symptoms were provided from premorbid
and prodromal stages associated with early impairment of the neuro-immuno-endocrine network, advanced biological age
and disruption of neurophysiological homeostasis. These alterations worsened with age, were gender-dependent and related
to increased vulnerability and mortality. This comprehensive multidimensional behavioral screening has provided a unique
tool to assess the potential preventive and/or therapeutic value of strategies based on life-style (voluntary and forced exercise),
psychological stimulation (postnatal handling, environmental enrichment, family structure), pharmacological interventions
(Melatonin, Huperzine A, Huprine-derivates, 5HT-4 agonists) and Ab-immunotherapy (scFv-h3D6). The contributions of
behavioral neuroscience from our and other laboratories offer a promising scenario for translational research.
Biography
Lydia Gimenez Llort completed her PhD from CSIC - University of Barcelona and postdoctoral studies from Karolinska Institutet. She is Associate Professor of
Psychiatry at the Department of Psychiatry and Forensic Medicine, Autonomous University of Barcelona. She is also member of the Institute of Neuroscience where
she was part of the Directive board and coordinator of the Master in Neuroscience. She founded the scientific network 4the5.net and she�s member of 2009-SGR-
0051, RETICEF (RD06/0013/0003), UCM-CM ENEROINN 910379 and Neurogenet Consortium. She represents Spain at the European COST-action TD1005 �Pain
Assessment in Patients with Impaired Cognition, especially Dementia�. She has published 70 papers in reputed journals.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals